Technical Analysis for SYGGF - Synairgen Plc

Grade Last Price % Change Price Change
A 2.62 -0.76% -0.0200
SYGGF closed down 0.76 percent on Friday, December 3, 2021, on 24 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical SYGGF trend table...

Date Alert Name Type % Chg
Stochastic Sell Signal Bearish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Overbought Stochastic Strength 0.00%
Gapped Down Weakness 0.00%
Volume Surge Other -0.76%
Outside Day Range Expansion -0.76%
Overbought Stochastic Strength -0.76%
Narrow Range Bar Range Contraction -3.14%
Older End-of-Day Signals for SYGGF ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Synairgen Plc Description

Synairgen plc discovers and develops drugs for respiratory diseases. It develops inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trial for the treatment or prevention of chronic obstructive pulmonary disease exacerbations caused by the common cold and flu; and LOXL2 inhibitor, which has completed Phase I clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF) and non-alcoholic fatty liver diseases. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor; and a strategic collaboration with Parexel Biotech on pivotal Phase III trial for the study of inhaled COVID-19 treatment. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Health Clinical Medicine Asthma Chronic Obstructive Pulmonary Disease Respiratory Diseases Chronic Lower Respiratory Diseases Idiopathic Pulmonary Fibrosis Common Cold Cytokines Interferon Pulmonary Fibrosis Pulmonology Parexel Antiviral Drugs

Is SYGGF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.84
52 Week Low 1.05
Average Volume 6,646
200-Day Moving Average 2.1667
50-Day Moving Average 2.3200
20-Day Moving Average 2.4510
10-Day Moving Average 2.4625
Average True Range 0.1042
ADX 17.71
+DI 38.9703
-DI 22.4908
Chandelier Exit (Long, 3 ATRs) 2.4174
Chandelier Exit (Short, 3 ATRs) 2.5127
Upper Bollinger Bands 2.7306
Lower Bollinger Band 2.1714
Percent B (%b) 0.8
BandWidth 22.8152
MACD Line 0.0655
MACD Signal Line 0.0416
MACD Histogram 0.0239
Fundamentals Value
Market Cap 523.77 Million
Num Shares 200 Million
EPS
Price-to-Sales 0.00
Price-to-Book 29.70
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.6200
Resistance 3 (R3) 2.6200 2.6200 2.6200
Resistance 2 (R2) 2.6200 2.6200 2.6200 2.6200
Resistance 1 (R1) 2.6200 2.6200 2.6200 2.6200 2.6200
Pivot Point 2.6200 2.6200 2.6200 2.6200 2.6200
Support 1 (S1) 2.6200 2.6200 2.6200 2.6200 2.6200
Support 2 (S2) 2.6200 2.6200 2.6200 2.6200
Support 3 (S3) 2.6200 2.6200 2.6200
Support 4 (S4) 2.6200